ACAD Acadia Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACAD

Price (delayed)

$28.38

Market cap

$4.89B

P/E Ratio

12.61

Dividend/share

N/A

EPS

$2.25

Enterprise value

$4.56B

?
Relative Growth: Rel. Growth: 77
Relative Strength: Rel. Strength: 70
Relative Valuation: Rel. Valuation: 73
Relative Profitability: Rel. Profitability: 93

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them ...

Highlights
The net income has surged by 71% year-on-year
The EPS has soared by 68% YoY
The quick ratio is up by 16% year-on-year but it has declined by 5% since the previous quarter
The debt has soared by 53% QoQ and by 34% YoY
The stock's price to earnings (P/E) is 9% more than its last 4 quarters average of 11.6
Sector: Healthcare
Industry: Biotechnology
Website: http://www.acadia-pharm.com
Peers: VNDA PFE JNJ BMY

Key stats

What are the main financial stats of ACAD

ACAD stock price

How has the Acadia Pharmaceuticals stock price performed over time
Intraday
-3.63%
1 week
-0.25%
1 month
11.29%
1 year
12.93%
YTD
6.25%
QTD
12.17%

Financial performance

How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$1.14B
Gross profit
$1.04B
Operating income
$86.37M
Net income
$380.48M
Gross margin
91.1%
Net margin
33.4%
The net income has surged by 71% year-on-year
The operating margin has shrunk by 67% YoY but it has increased by 2.7% QoQ
The operating income has plunged by 64% YoY but it has grown by 7% from the previous quarter
The net margin has soared by 53% YoY but it has decreased by 2.6% QoQ

Price vs fundamentals

How does ACAD's price correlate with its fundamentals

Growth

What is Acadia Pharmaceuticals's growth rate over time

Valuation

What is Acadia Pharmaceuticals stock price valuation
ACAD P/E details
P/E
12.61
P/B
3.72
P/S
4.28
EV/EBIT
37.54
EV/EBITDA
34.16
EV/Sales
4
The EPS has soared by 68% YoY
The stock's price to earnings (P/E) is 9% more than its last 4 quarters average of 11.6
The company's equity has surged by 59% YoY and by 4.7% QoQ
ACAD's price to book (P/B) is 38% lower than its 5-year quarterly average of 6.0 but 6% higher than its last 4 quarters average of 3.5
ACAD's P/S is 16% above its last 4 quarters average of 3.7 but 11% below its 5-year quarterly average of 4.8
ACAD's revenue is up by 12% YoY and by 4% QoQ

Efficiency

How efficient is Acadia Pharmaceuticals business performance
ACAD's return on invested capital has dropped by 76% year-on-year and by 6% since the previous quarter
The ROS has shrunk by 59% YoY
Acadia Pharmaceuticals's return on assets has increased by 24% YoY but it has decreased by 7% QoQ
The ROE has contracted by 9% from the previous quarter but it has grown by 6% YoY

Dividends

What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACAD.

Financial health

How did Acadia Pharmaceuticals financials performed over time
The total assets has grown by 42% YoY and by 9% from the previous quarter
The total liabilities has increased by 22% QoQ and by 8% YoY
The debt is 95% lower than the equity
The debt to equity has surged by 67% since the previous quarter
The company's equity has surged by 59% YoY and by 4.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.